-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616

Benzinga·06/02/2026 17:03:25
Listen to the news
Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.